You are using an older browser version. Please use a supported version for the best MSN experience.

BioMarin CEO expects 'substantial' profitability after FDA approval of hemophilia drug

Jim Cramer chats with Jean-Jacques Bienaimé, chairman and CEO of BioMarin, which focuses on therapies to treat rare diseases.
image beaconimage beaconimage beacon